DK2902018T3 - Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater - Google Patents
Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater Download PDFInfo
- Publication number
- DK2902018T3 DK2902018T3 DK14194703.6T DK14194703T DK2902018T3 DK 2902018 T3 DK2902018 T3 DK 2902018T3 DK 14194703 T DK14194703 T DK 14194703T DK 2902018 T3 DK2902018 T3 DK 2902018T3
- Authority
- DK
- Denmark
- Prior art keywords
- implant
- prostaglandin
- eye
- use according
- implants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Prostaglandin til anvendelse i behandling af forhøjet intraokulært tryk (IOP) ved placering af et biologisk nedbrydeligt intraokulært implantat i et øje på en patient med behov for behandlingen; hvor: implantatet omfatter en prostaglandin i en mængde af 15-25 vægt-% af implantatets vægt, hvor prostaglandinen er forbundet med en biologisk nedbrydelig polymermatrix, derfrigiver en mængde af prostaglandinen, der er effektiv til at forebygge eller mindske et symptom på forhøjet IOP; og implantatet placeres i en intracameral lokalitet ved kl. 6-positionen for at udvide øjets afløbskanaler, der udgår fra Schlemms kanal, og for derved at blande prostaglandinen godt over hele det forreste segment via konvektionsstrømmene.
2. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres på en intracameral lokalitet ved kl. 6-positionen for at udvide karrene i det episclerale og conjunctivale veneplexus.
3. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres ved kl. 6-positionen i øjets forreste øjenkammer.
4. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres ved kl. 6-positionen i øjets iridocorneale vinkel.
5. Prostaglandin til anvendelse ifølge krav 1, hvor implantatet placeres i øjet ved anvendelse af en okulær implantatindføringsanordning omfattende: (a) en kanyle med en ydre væg, en proximal ende, en proximal endeåbning, en distal ende, en distal endeåbning og et lumen, der strækker sig gennem kanylen; (b) et okulært transplantat, der er dimensioneret og struktureret til implantation i et øje, hvilket okulære implantat placeres i lumenet; og (c) en kappe med en lukket distal ende, som er i kontakt med den ydre væg af kanylen og dækker kanylens distale ende og distale endeåbning, hvilken kappe er struktureret til at tillade, at kanylens distale ende og distale endeåbning passerer gennem kappen, når kanylen føres ind i et øje.
6. Prostaglandin til anvendelse ifølge krav 1, hvor prostaglandinen er en forbindelse med formlen (I):
hvor kortstregsbindingerne repræsenterer en enkelt- eller dobbeltbinding, der kan være i cis- eller trans-konfigurationen, A er et alkylen- eller alkenylenradikal med fra to til seks carbonatomer, hvilket radikal kan være afbrudt af ét eller flere oxidradikaler og substitueret med én eller flere hydroxy-, oxo-, alkyloxy- eller akylcarboxygrupper, hvor alkylradikalet omfatter fra ét til seks carbonatomer; B er et cycloalkylradikal med fra tre til syv carbonatomer, eller et arylradikal, der er udvalgt fra gruppen bestående af hydrocarbylaryl- og heteroarylradikaler med fra fire til ti carbonatomer, hvor heteroatomet er udvalgt fra gruppen bestående af nitrogen-, oxygen- og svovlatomer; X er -(OR4), hvor R4 er uafhængigt udvalgt fra gruppen bestående af hydrogen og et lavere alkylradikal med fra ét til seks carbonatomer; Z er =0; ét af Ri og R2 er =0, -OH eller en -0(C0)Re-gruppe, og det andet er -OH eller - 0(C0)R6, eller Ri er =0 og R2 er H; hvor R6 er en mættet eller umættet acyklisk carbonhydridgruppe med fra 1 til ca. 20 carbonatomer, eller -(CH2)mR7, hvor m er 0-10, og R7 er et cycloalkylradikal med fra tre til syv carbonatomer, eller hydrocarbylaryl eller heteroaryl, som defineret ovenfor.
7. Prostaglandin til anvendelse ifølge krav 6, hvor prostaglandinen har følgende formel (II):
hvor y er 0 eller 1, x er 0 eller 1 og x+y ikke begge er 1, Y er et radikal udvalgt fra gruppen bestående af alkyl, halo, nitro, amino, thiol, hydroxy, alkyloxy, alkylcarboxy og halo-substitueret alkyl, hvor alkylradikalet omfatter fra ét til seks carbonatomer, n er 0 eller et heltal på fra 1 til 3 og R3 er =0, —OH eller --0(C0)R.6 og kortstregslinjerne indikerer alfa-konfigurationen og fyldte trekanter indikerer beta-konfigurationen.
8. Prostaglandin til anvendelse ifølge krav 7, hvor prostaglandinen omfatter latanoprost, travoprost, salte deraf eller blandinger deraf.
9. Prostaglandin til anvendelse ifølge krav 8, hvor IOP'et reduceres med mindst 60 % i forhold til baseline.
10. Prostaglandin til anvendelse ifølge et hvilket som helst af de foregående krav, hvor diameteren af implantatet er mindre end 500 pm.
11. Prostaglandin til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor implantatet er dimensioneret til at passe til anatomien af øjets iridocorneale vinkel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/761,765 US8673341B2 (en) | 2004-04-30 | 2010-04-16 | Intraocular pressure reduction with intracameral bimatoprost implants |
| EP11717096.9A EP2558081B1 (en) | 2010-04-16 | 2011-04-14 | Intraocular pressure reduction with intracameral bimatoprost implants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2902018T3 true DK2902018T3 (da) | 2017-03-06 |
Family
ID=44194969
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14194703.6T DK2902018T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale bimatoprost-implantater |
| DK16201104.3T DK3205333T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale prostamid-implantater |
| DK11717096T DK2558081T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intrakamerale bimatoprost-implantater |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16201104.3T DK3205333T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intracamerale prostamid-implantater |
| DK11717096T DK2558081T3 (da) | 2010-04-16 | 2011-04-14 | Reduktion af intraokulært tryk med intrakamerale bimatoprost-implantater |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8673341B2 (da) |
| EP (5) | EP3205333B1 (da) |
| JP (5) | JP5982360B2 (da) |
| KR (2) | KR101915326B1 (da) |
| CN (2) | CN111450041A (da) |
| AU (1) | AU2011239642B2 (da) |
| BR (1) | BR112012026535A2 (da) |
| CA (2) | CA2796443C (da) |
| CY (3) | CY1115912T1 (da) |
| DK (3) | DK2902018T3 (da) |
| ES (3) | ES2528117T3 (da) |
| HU (2) | HUE040529T2 (da) |
| IL (1) | IL222457A (da) |
| MX (2) | MX385821B (da) |
| PL (3) | PL2902018T3 (da) |
| PT (3) | PT3205333T (da) |
| RU (1) | RU2586298C2 (da) |
| SG (2) | SG10201606415UA (da) |
| SI (3) | SI2902018T1 (da) |
| TR (1) | TR201820663T4 (da) |
| WO (1) | WO2011130462A2 (da) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| WO2002080811A2 (en) | 2001-04-07 | 2002-10-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US9498457B2 (en) * | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| WO2008061043A2 (en) | 2006-11-10 | 2008-05-22 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| AU2009221859B2 (en) | 2008-03-05 | 2013-04-18 | Alcon Inc. | Methods and apparatus for treating glaucoma |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2015073571A1 (en) * | 2013-11-15 | 2015-05-21 | Dose Medical Corporation | Ocular implants configured to store and release stable drug formulations |
| EP2432420A4 (en) | 2009-05-18 | 2018-01-10 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| EP2437684B1 (en) | 2009-06-03 | 2022-06-15 | ForSight Vision5, Inc. | Anterior segment drug delivery |
| JP5635605B2 (ja) | 2009-07-09 | 2014-12-03 | イバンティス インコーポレイテッド | 眼内インプラント及び眼内インプラントを眼球内に送出するための方法 |
| US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
| CN102821753A (zh) | 2010-01-22 | 2012-12-12 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
| EP2571526B1 (en) | 2010-05-17 | 2019-03-13 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US20120276186A1 (en) | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| JP5989780B2 (ja) | 2011-09-14 | 2016-09-07 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | 眼挿入装置および方法 |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| EP3342380B1 (en) | 2012-03-26 | 2024-12-04 | Glaukos Corporation | System for delivering multiple ocular implants |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| RU2652063C2 (ru) | 2012-10-26 | 2018-04-24 | Форсайт Вижн5, Инк. | Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу |
| WO2014066653A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release intraocular drug delivery systems |
| US20150272877A1 (en) * | 2012-10-26 | 2015-10-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| WO2014143754A2 (en) * | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| EP2978406A1 (en) * | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| AU2014248460B2 (en) | 2013-04-01 | 2019-04-11 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| PT3062775T (pt) * | 2013-10-31 | 2018-03-06 | Allergan Inc | Implantes intraoculares contendo prostamida e métodos para a sua utilização |
| AU2015266850B2 (en) | 2014-05-29 | 2019-12-05 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| WO2017015675A1 (en) * | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Glaucoma treatment via intracameral ocular implants |
| EP4265231A3 (en) | 2015-08-14 | 2023-12-20 | Alcon Inc. | Ocular implant with pressure sensor |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| EP3515406B1 (en) | 2016-09-23 | 2024-07-24 | Incept, LLC | Intracameral drug delivery depots |
| USD841152S1 (en) | 2017-06-27 | 2019-02-19 | Monica S. Naylor | Eye drop container |
| WO2019070385A2 (en) | 2017-10-06 | 2019-04-11 | Glaukos Corporation | SYSTEMS AND METHODS FOR PLACING MULTIPLE OCULAR IMPLANTS |
| USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
| EP3755287B1 (en) | 2018-02-22 | 2024-04-03 | Alcon Inc. | Ocular implant |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
| AU2020302924A1 (en) | 2019-06-27 | 2022-02-17 | Layerbio, Inc. | Ocular device delivery methods and systems |
| PT3861985T (pt) | 2020-02-06 | 2023-08-03 | Ocular Therapeutix Inc | Composições e métodos para tratar doenças oculares |
| EP4142664A4 (en) | 2020-04-27 | 2024-05-29 | Ocular Therapeutix, Inc. | METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS |
| JP7579594B2 (ja) | 2020-05-15 | 2024-11-08 | アイフロー・インコーポレーテッド | 哺乳類の眼の従来の房水排出路内の移植物のための方法及び装置 |
| CA3202776A1 (en) | 2021-01-11 | 2022-07-14 | Wayne A. Noda | Systems and methods for viscoelastic delivery |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT252264B (de) | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates |
| US3393081A (en) * | 1966-12-06 | 1968-07-16 | Monsanto Co | Heat sealable moisture barrier coatings for polystyrene articles |
| US3749776A (en) | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| SE390255B (sv) | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US3966749A (en) | 1975-02-10 | 1976-06-29 | Interx Research Corporation | Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4052505A (en) | 1975-05-30 | 1977-10-04 | Alza Corporation | Ocular therapeutic system manufactured from copolymer |
| US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4057619A (en) | 1975-06-30 | 1977-11-08 | Alza Corporation | Ocular therapeutic system with selected membranes for administering ophthalmic drug |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4186184A (en) | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4190642A (en) | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285957A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
| US4303637A (en) | 1980-04-04 | 1981-12-01 | Alza Corporation | Medication indicated for ocular hypertension |
| US4281654A (en) | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4396625A (en) | 1980-05-13 | 1983-08-02 | Sumitomo Chemical Company, Limited | Treatment of glaucoma or ocular hypertension and ophthalmic composition |
| US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| DE3220156C2 (de) | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
| US4649151A (en) | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4478818A (en) | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4675338A (en) | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4693885A (en) | 1984-07-18 | 1987-09-15 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| FR2577509B1 (fr) | 1985-02-21 | 1987-05-07 | Nirvana Espar Systems Sa | Mat de bateau a voile |
| US4656186A (en) | 1985-04-30 | 1987-04-07 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| FR2594438B1 (fr) | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| CA1311686C (en) | 1986-06-25 | 1992-12-22 | John Weldon Shell | Controlled release bioerodible drug delivery system |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5089509A (en) | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US4981871A (en) | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4865846A (en) | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US5190966A (en) | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US5198460A (en) | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
| US5093349A (en) | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| WO1990002553A1 (en) | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US4935498A (en) | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US4932984A (en) | 1989-07-27 | 1990-06-12 | The Dow Chemical Company | Process for reduction of chlorinated solvent emissions |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US5268178A (en) | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
| US5503721A (en) | 1991-07-18 | 1996-04-02 | Hri Research, Inc. | Method for photoactivation |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5075115A (en) | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
| US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| US5196460A (en) * | 1990-05-29 | 1993-03-23 | Repap Technologies Inc. | Rubber compositions containing high purity lignin derivatives |
| US5100431A (en) | 1990-09-27 | 1992-03-31 | Allergan, Inc. | Single stitch suture needle and method |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| CA2055522A1 (en) | 1990-12-12 | 1992-06-13 | Masako Andoh | Microspheres for ophthalmic use |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| DE69213739T2 (de) | 1991-06-21 | 1997-02-20 | Genetics Institute, Inc., Cambridge, Mass. | Osteogene proteine enthaltende arzneimittel |
| US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| IT1263116B (it) | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
| US5655832A (en) | 1992-04-16 | 1997-08-12 | Tir Technologies, Inc. | Multiple wavelength light processor |
| US5244914A (en) | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| DE4403326C1 (de) | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6270492B1 (en) | 1994-09-09 | 2001-08-07 | Cardiofocus, Inc. | Phototherapeutic apparatus with diffusive tip assembly |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| MX9700850A (es) | 1995-06-09 | 1997-09-30 | Euro Celtique Sa | Formulaciones y metodos para proporcionar anestesia local prolongada. |
| US5906920A (en) | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
| US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| WO1998010758A1 (en) | 1996-09-13 | 1998-03-19 | The Regents Of The University Of California | Methods for treatment of retinal diseases |
| US5913884A (en) | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
| US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
| US6274614B1 (en) | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| AU727080B2 (en) | 1997-06-30 | 2000-11-30 | Allergan, Inc. | Calcium blockers to treat proliferative vitreoretinopathy |
| JP2001513369A (ja) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法 |
| US6306426B1 (en) | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| FR2767699A1 (fr) * | 1997-08-28 | 1999-02-26 | Oreal | Composition filmogene epaissie |
| US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US6271220B1 (en) | 1998-03-11 | 2001-08-07 | Allergan Sales, Inc. | Anti-angiogenic agents |
| AU4645099A (en) | 1998-07-09 | 2000-02-01 | Yoram Harth | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
| ATE269114T1 (de) | 1998-11-20 | 2004-07-15 | Univ Connecticut | Verfahren und vorrichtung zur steuerung der gewebeimplantat-interaktionen |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| US6290713B1 (en) | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
| US6317616B1 (en) | 1999-09-15 | 2001-11-13 | Neil David Glossop | Method and system to facilitate image guided surgery |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| EP1096719A3 (en) | 1999-11-01 | 2007-12-05 | Matsushita Electric Industrial Co., Ltd. | Relay data retransmission method and system |
| US6319273B1 (en) | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| US6395787B1 (en) | 2000-02-08 | 2002-05-28 | Allergan Sales, Inc. | Ocular hypotensive lipids |
| WO2001058240A2 (en) | 2000-02-10 | 2001-08-16 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy for treating conditions of the eye |
| US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| IL151530A0 (en) | 2000-07-14 | 2003-04-10 | Allergan Sales Inc | Compositions containing alpha-2-adrenergic agonist components |
| US6357568B1 (en) | 2000-09-27 | 2002-03-19 | Shou Mao Chen | Structure for protecting a luggage shell |
| WO2002058730A2 (en) | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| EP1339438B1 (en) | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| EP1387671A1 (en) | 2001-05-03 | 2004-02-11 | MASSACHUSETTS EYE & EAR INFIRMARY | Implantable drug delivery device and use thereof |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US6713268B2 (en) | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| US20030220376A1 (en) | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| AU2002341881B2 (en) | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| AU2003257588A1 (en) | 2002-08-29 | 2004-03-19 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| CN1301692C (zh) * | 2002-09-18 | 2007-02-28 | 阿勒根公司 | 眼植入物导入的器械 |
| RU2355385C2 (ru) | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
| JP2004196787A (ja) | 2002-12-04 | 2004-07-15 | Santen Pharmaceut Co Ltd | 結膜下デポによるドラッグデリバリーシステム |
| US20040137059A1 (en) | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US7186744B2 (en) | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| EP1711186A4 (en) | 2004-02-04 | 2009-03-18 | Retmed Pty Ltd | SLOWLY RELEASED STEROID COMPOSITION |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244478A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20050244465A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
| US20050244471A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244466A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244462A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20050244461A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7091231B2 (en) | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| EP1856042B1 (en) | 2005-03-10 | 2012-06-27 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7585895B2 (en) | 2005-12-06 | 2009-09-08 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| US7427685B2 (en) | 2005-12-06 | 2008-09-23 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| CN101330914A (zh) | 2005-12-16 | 2008-12-24 | 爱尔康公司 | 使用alk5调节剂控制眼内压 |
| EP1978892B1 (en) | 2006-01-17 | 2017-11-15 | Novartis Ag | Drug delivery treatment device |
| KR20140093764A (ko) * | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| US7592364B2 (en) | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US7589213B2 (en) | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US7947732B2 (en) | 2007-07-13 | 2011-05-24 | Allergan, Inc. | Therapeutic substituted chlorocyclopentanols |
| US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
| IL186598A0 (en) | 2007-10-11 | 2008-11-03 | Mohammad Abdulrazik | Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| MX2010005105A (es) | 2007-11-09 | 2010-05-27 | Allergan Inc | Ciclopentanos substituidos que comprenden actividad de prostaglandina. |
| US20110152328A1 (en) | 2008-04-16 | 2011-06-23 | Whitcup Scott M | Combination Therapy For Glaucoma |
| UA103616C2 (ru) | 2008-04-24 | 2013-11-11 | Аллерган, Инк. | Замещенные гамма-лактамы как терапевтические агенты |
| EP2296621A1 (en) | 2008-05-20 | 2011-03-23 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100098772A1 (en) | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US9636255B2 (en) * | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US20100247606A1 (en) | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| AU2010276648A1 (en) | 2009-07-30 | 2012-02-23 | Allergan, Inc. | Selective alpha 2B/2C agonists |
| US20120245505A1 (en) | 2009-12-16 | 2012-09-27 | Robinson Michael R | Intracameral devices for sustained delivery |
| CN102821753A (zh) * | 2010-01-22 | 2012-12-12 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
| WO2011109384A2 (en) | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
-
2010
- 2010-04-16 US US12/761,765 patent/US8673341B2/en not_active Expired - Fee Related
-
2011
- 2011-04-14 DK DK14194703.6T patent/DK2902018T3/da active
- 2011-04-14 SG SG10201606415UA patent/SG10201606415UA/en unknown
- 2011-04-14 EP EP16201104.3A patent/EP3205333B1/en active Active
- 2011-04-14 PL PL14194703T patent/PL2902018T3/pl unknown
- 2011-04-14 KR KR1020127029910A patent/KR101915326B1/ko not_active Expired - Fee Related
- 2011-04-14 EP EP23202362.2A patent/EP4316594A3/en not_active Withdrawn
- 2011-04-14 MX MX2014008487A patent/MX385821B/es unknown
- 2011-04-14 CA CA2796443A patent/CA2796443C/en active Active
- 2011-04-14 EP EP11717096.9A patent/EP2558081B1/en active Active
- 2011-04-14 EP EP18187001.5A patent/EP3456323A1/en not_active Withdrawn
- 2011-04-14 BR BR112012026535A patent/BR112012026535A2/pt not_active Application Discontinuation
- 2011-04-14 PL PL11717096T patent/PL2558081T3/pl unknown
- 2011-04-14 PT PT16201104T patent/PT3205333T/pt unknown
- 2011-04-14 EP EP14194703.6A patent/EP2902018B1/en active Active
- 2011-04-14 DK DK16201104.3T patent/DK3205333T3/da active
- 2011-04-14 JP JP2013505123A patent/JP5982360B2/ja not_active Expired - Fee Related
- 2011-04-14 SI SI201131120A patent/SI2902018T1/sl unknown
- 2011-04-14 KR KR1020187030085A patent/KR102252437B1/ko not_active Expired - Fee Related
- 2011-04-14 WO PCT/US2011/032393 patent/WO2011130462A2/en not_active Ceased
- 2011-04-14 ES ES11717096.9T patent/ES2528117T3/es active Active
- 2011-04-14 HU HUE16201104A patent/HUE040529T2/hu unknown
- 2011-04-14 SI SI201131645T patent/SI3205333T1/sl unknown
- 2011-04-14 AU AU2011239642A patent/AU2011239642B2/en not_active Ceased
- 2011-04-14 SG SG2012077079A patent/SG184905A1/en unknown
- 2011-04-14 PL PL16201104T patent/PL3205333T3/pl unknown
- 2011-04-14 SI SI201130419T patent/SI2558081T1/sl unknown
- 2011-04-14 ES ES16201104T patent/ES2707801T3/es active Active
- 2011-04-14 CA CA3010374A patent/CA3010374A1/en not_active Abandoned
- 2011-04-14 MX MX2012012040A patent/MX2012012040A/es active IP Right Grant
- 2011-04-14 ES ES14194703.6T patent/ES2617285T3/es active Active
- 2011-04-14 PT PT117170969T patent/PT2558081E/pt unknown
- 2011-04-14 HU HUE14194703A patent/HUE033186T2/en unknown
- 2011-04-14 TR TR2018/20663T patent/TR201820663T4/tr unknown
- 2011-04-14 DK DK11717096T patent/DK2558081T3/da active
- 2011-04-14 RU RU2012147550/15A patent/RU2586298C2/ru active
- 2011-04-14 CN CN202010034408.6A patent/CN111450041A/zh active Pending
- 2011-04-14 CN CN201180027636.XA patent/CN103002884B/zh not_active Expired - Fee Related
- 2011-04-14 PT PT141947036T patent/PT2902018T/pt unknown
-
2012
- 2012-10-15 IL IL222457A patent/IL222457A/en active IP Right Grant
-
2014
- 2014-03-07 US US14/201,194 patent/US20140316009A1/en not_active Abandoned
-
2015
- 2015-01-21 CY CY20151100056T patent/CY1115912T1/el unknown
-
2016
- 2016-06-03 JP JP2016111665A patent/JP6416154B2/ja active Active
-
2017
- 2017-02-24 CY CY20171100261T patent/CY1120299T1/el unknown
-
2018
- 2018-10-03 JP JP2018188114A patent/JP6683787B2/ja active Active
- 2018-12-27 CY CY181101399T patent/CY1121064T1/el unknown
-
2020
- 2020-03-26 JP JP2020055435A patent/JP6946503B2/ja active Active
-
2021
- 2021-09-15 JP JP2021150124A patent/JP2022000441A/ja active Pending
-
2023
- 2023-12-15 US US18/541,570 patent/US20240277609A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240277609A1 (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| KR102126007B1 (ko) | 전방내 서방성 치료제 이식물 | |
| US20230026451A1 (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| HK1244665A1 (en) | Intraocular pressure reduction with intracameral prostamide implants | |
| HK1244665B (en) | Intraocular pressure reduction with intracameral prostamide implants | |
| HK1183436A (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| HK1183436B (zh) | 用前房内比马前列素植入物的眼内压降低 |